NIH [to 16 January 2016]
http://www.nih.gov/news/releases.htm

.
January 14, 2016
Dengue vaccine enters phase 3 trial in Brazil
— Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The Butantan Institute, a non-profit producer of immunobiologic products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo…

.
January 12, 2016
New NIH awards will support development of therapeutic alternatives to traditional antibiotics
— NIAID has awarded approximately $5 million in funding for 24 research projects seeking to develop non-traditional therapeutics for bacterial infections.